Skip to main content
BDX
NYSE Industrial Applications And Services

BD Tops Q3 Forecasts and Lifts Full-Year EPS Guidance Midpoint

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$172
Mkt Cap
$47.024B
52W Low
$127.536
52W High
$187.35
52W Position info
35% above low
Off High info
8.2% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

BDX sits 35% above its 52-week low of $127.536.

Summary

BD posted Q3 fiscal 2026 revenue of $5.0 billion, up 5.4%, with adjusted EPS of $3.23 beating expectations. The company raised the midpoint of its full-year adjusted EPS guidance and highlighted strong cash flow growth.


Key Events · Earnings and Guidance · BDX

  • Q3 Revenue and EPS Beat

    Revenue of $5.0 billion grew 5.4% reported, or 4.4% on a currency-neutral basis. Adjusted diluted EPS of $3.23 exceeded expectations, driven by strength across all four segments.

  • Full-Year Guidance Raised

    BD raised the midpoint of its adjusted diluted EPS guidance to $12.62–$12.72 from $12.52–$12.72, and now expects revenue growth toward the high end of its low single-digit plus range.

  • Cash Flow Surge

    Year-to-date cash from continuing operations increased 33.3% to $2.1 billion, and free cash flow jumped 44.6% to $1.7 billion, reflecting improved working capital and profitability.

  • First Full Quarter as Pure-Play MedTech

    These results represent the first full quarter following the February 2026 spin-off of the Biosciences and Diagnostic Solutions business, showcasing the focused 'New BD' strategy.


Analysis · BDX · Industrial Applications And Services

A strong third quarter saw BD surpass expectations on revenue, adjusted operating margin, and adjusted EPS. Reflecting sustained momentum across all four segments, the company raised the midpoint of its full-year adjusted diluted EPS guidance to $12.62–$12.72. Cash generation improved markedly, with year-to-date free cash flow climbing 44.6% to $1.7 billion, which provides ample capacity for strategic capital deployment. These results mark the first full quarter as a pure-play MedTech company following the spin-off of the Biosciences and Diagnostic Solutions business.

How filings like this one have moved

In the 30 days to Nov 5, 2026, 33.4% of the 2397 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BDX was trading at $172.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $47B. The 52-week trading range was $127.54 to $187.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BDX - Latest Insights

BDX
Nov 05, 2026, 6:54 AM EST
Source: dpa-AFX
Importance Score:
7
Price at Filing: $206.00
Real-time Price: $206.00 info
Change: $0 (0%) info
Market Cap: $56.981B info
BDX
Nov 05, 2026, 6:31 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $204.07
Real-time Price: $206.00 info
Change: +$1.93 (+0.95%) info
Market Cap: $56.981B info
BDX
Nov 05, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $205.50
Real-time Price: $206.00 info
Change: +$0.500 (+0.24%) info
Market Cap: $56.981B info
BDX
Oct 07, 2026, 1:00 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $181.41
Real-time Price: $206.00 info
Change: +$24.60 (+14%) info
Market Cap: $56.981B info
BDX
Oct 07, 2026, 8:20 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $177.43
Real-time Price: $206.00 info
Change: +$28.57 (+16%) info
Market Cap: $56.981B info